Rep. Gilbert Ray Cisneros, Jr. Purchases Shares of Tandem Diabetes Care, Inc. (NASDAQ:TNDM)

Representative Gilbert Ray Cisneros, Jr. (D-California) recently bought shares of Tandem Diabetes Care, Inc. (NASDAQ:TNDM). In a filing disclosed on April 07th, the Representative disclosed that they had bought between $1,001 and $15,000 in Tandem Diabetes Care stock on March 4th. The trade occurred in the Representative's "150 MAIN STREET TRUST > BANK OF AMERICA" account.

Representative Gilbert Ray Cisneros, Jr. also recently made the following trade(s):

• Purchased $15,001 - $50,000 in shares of PTC NASDAQ: PTC on 4/1/2025.
• Sold $1,001 - $15,000 in shares of W. R. Berkley NYSE: WRB on 4/1/2025.
• Sold $15,001 - $50,000 in shares of GoDaddy NYSE: GDDY on 4/1/2025.
• Purchased $1,001 - $15,000 in shares of Ford Motor NYSE: F on 3/31/2025.
• Sold $15,001 - $50,000 in shares of Microsoft NASDAQ: MSFT on 3/31/2025.
• Sold $15,001 - $50,000 in shares of Pfizer NYSE: PFE on 3/31/2025.
• Purchased $1,001 - $15,000 in shares of Boeing NYSE: BA on 3/31/2025.
• Sold $1,001 - $15,000 in shares of Hologic NASDAQ: HOLX on 3/31/2025.
• Sold $15,001 - $50,000 in shares of Merck & Co., Inc. NYSE: MRK on 3/31/2025.
• Sold $1,001 - $15,000 in shares of Tesla NASDAQ: TSLA on 3/31/2025.

Tandem Diabetes Care Stock Performance

Shares of NASDAQ:TNDM traded down $0.51 during trading on Monday, reaching $16.55. 761,299 shares of the stock were exchanged, compared to its average volume of 1,497,457. Tandem Diabetes Care, Inc. has a 12 month low of $15.75 and a 12 month high of $53.69. The stock has a 50-day moving average price of $23.62 and a 200-day moving average price of $30.82. The company has a current ratio of 2.90, a quick ratio of 2.32 and a debt-to-equity ratio of 1.29. The firm has a market cap of $1.10 billion, a PE ratio of -8.58 and a beta of 1.52.

Remove Ads

Analyst Upgrades and Downgrades

A number of research analysts have commented on the company. Robert W. Baird decreased their price objective on Tandem Diabetes Care from $37.00 to $33.00 and set a "neutral" rating on the stock in a report on Thursday, February 27th. Canaccord Genuity Group reissued a "buy" rating and issued a $63.00 price objective on shares of Tandem Diabetes Care in a report on Wednesday, February 26th. Morgan Stanley downgraded shares of Tandem Diabetes Care from an "overweight" rating to an "equal weight" rating and dropped their price target for the company from $45.00 to $22.00 in a research report on Wednesday, March 5th. Mizuho assumed coverage on Tandem Diabetes Care in a research note on Thursday. They set a "neutral" rating and a $20.00 price objective on the stock. Finally, Citigroup downgraded Tandem Diabetes Care from a "buy" rating to a "neutral" rating and reduced their target price for the company from $35.00 to $24.00 in a report on Tuesday, March 4th. Nine investment analysts have rated the stock with a hold rating and eleven have given a buy rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $43.88.

Insider Buying and Selling

In other news, COO Jean-Claude Kyrillos acquired 10,538 shares of the firm's stock in a transaction on Friday, March 7th. The stock was purchased at an average price of $18.12 per share, for a total transaction of $190,948.56. Following the purchase, the chief operating officer now owns 10,538 shares in the company, valued at approximately $190,948.56. This represents a ∞ increase in their position. The purchase was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 2.20% of the stock is currently owned by corporate insiders.

Institutional Trading of Tandem Diabetes Care

Several hedge funds have recently bought and sold shares of the business. Captrust Financial Advisors grew its holdings in shares of Tandem Diabetes Care by 19.3% during the third quarter. Captrust Financial Advisors now owns 10,170 shares of the medical device company's stock valued at $431,000 after buying an additional 1,647 shares during the last quarter. Point72 Asset Management L.P. bought a new stake in Tandem Diabetes Care during the 3rd quarter worth approximately $10,208,000. Point72 DIFC Ltd bought a new stake in Tandem Diabetes Care during the 3rd quarter worth approximately $130,000. Quantinno Capital Management LP raised its stake in shares of Tandem Diabetes Care by 43.1% in the third quarter. Quantinno Capital Management LP now owns 31,145 shares of the medical device company's stock worth $1,321,000 after purchasing an additional 9,385 shares during the last quarter. Finally, Stifel Financial Corp lifted its holdings in shares of Tandem Diabetes Care by 6.8% in the third quarter. Stifel Financial Corp now owns 34,072 shares of the medical device company's stock valued at $1,445,000 after purchasing an additional 2,160 shares in the last quarter.

About Representative Cisneros

Gil Cisneros (Democratic Party) is a member of the U.S. House, representing California's 31st Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027. Cisneros (Democratic Party) is running for re-election to the U.S. House to represent California's 31st Congressional District. He declared candidacy for the 2026 election. Gil Cisneros served in the U.S. Navy as a supply officer from 1994 to 2004. Cisneros earned a bachelor's degree in political science from George Washington University in 1994, a master's in business administration from Regis University in 2002, and a master's degree in urban education policy from Brown University in 2015. His career experience includes working as a logistics manager for Frito-Lay. In 2010, Cisneros won the lottery and became involved in activism and philanthropy, founding a scholarship program for local high school students. In 2021, President Joe Biden (D) appointed Cisneros as under secretary of defense for personnel and readiness.

Tandem Diabetes Care Company Profile

Tandem Diabetes Care, Inc, a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system.